Ann: Kazia Half Year Accounts and Chairman's letter, page-87

Sorry RP yes that's one application cohort only brutally one revenue stream potential of 1.5 billion usd - 2.2 billion odd Aud per annum... ie 10 years 22 billion AUD

And of course we have multiple concurrent trials we may find Paxalisib will benefit other patients - in fact its been shown so much support by clinicians I think it's almost inevitable we'll get more use cases - this is all very exciting for patients and feeds the

"the ever-growing enthusiasm of clinicians"

a statement like like that is not one made if clinicians are moving on to other focuses.